Evaluation of Filgrastim Therapy in Kidney Transplant Recipients

Context: Neutropenia is associated with a high risk of serious infections in kidney transplant recipients. There are no sufficient studies of using granulocyte colony-stimulating factors, such as filgrastim, in renal transplant recipients to establish a clear, specified role of this off-label indication. Using filgrastim in these patients may increase the risk of rejection by overstimulating the immune system. Objective: To evaluate the use of filgrastim in adult kidney transplant recipients presenting with neutropenia. Patients and Design: Data were obtained from a medication utilization report of filgrastim in kidney transplant recipients at our center from September 2012 to August 2015. Main Outcome Measure(s) and Results: There were 28 cases of neutropenia that were treated with a range of 1 to 5 doses of filgrastim 300 or 480 μg, with a mean of 1.79 doses. The mean total dose of filgrastim administered per episode of neutropenia was 632 μg (8.6 μg/kg). Overall, 87.5% of the cases achieved a white blood cell count of at least 3 × 109 cells/L within 7 days of hospital discharge. There were no cases of infection or acute rejection following treatment. Conclusions: The use of filgrastim in kidney transplant recipients demonstrated success in reversing neutropenia. Short courses of therapy were required with minimal adverse events. Patients who required readmission were successfully re-treated. Additional studies are required to determine the most effective dose and duration of treatment.

Download Full-text

The Role of Resilience in Healthcare Transitions among Adolescent and Young Adult Kidney Transplant Recipients

Journal of Adolescent Health ◽

10.1016/j.jadohealth.2017.11.034 ◽

2018 ◽

Vol 62 (2) ◽

pp. S16-S17

Author(s):

Sheila M. Quin ◽

Hilda Fernandez ◽

Taylor McCorkle ◽

Saarah Hussain ◽

Rachel S. Rogers ◽

...

Keyword(s):

Young Adult ◽

Kidney Transplant ◽

Adolescent And Young Adult ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Adult Kidney

Download Full-text

PREVALENCE OF LATE POSTTRANSPLANT ANEMIA IN ADULT KIDNEY TRANSPLANT RECIPIENTS AND THE ROLE OF SIROLIMUS - A SINGLE CENTRE STUDY

Transplantation Journal ◽

10.1097/00007890-201007272-01388 ◽

2010 ◽

Vol 90 ◽

pp. 720

Author(s):

R. Slavickova ◽

V. Lanska ◽

M. Stollova ◽

O. Viklicky

Keyword(s):

Kidney Transplant ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Single Centre ◽

Centre Study ◽

Adult Kidney ◽

Single Centre Study

Download Full-text

POST-TRANSPLANT FUNCTIONAL STATUS TRAJECTORY AMONG ADULT KIDNEY TRANSPLANT RECIPIENTS

Innovation in Aging ◽

10.1093/geroni/igz038.2921 ◽

2019 ◽

Vol 3 (Supplement_1) ◽

pp. S793-S793

Author(s):

Nadia M Chu ◽

Zhan Shi ◽

Christine Haugen ◽

Dorry Segev ◽

Mara McAdams-DeMarco

Keyword(s):

Functional Status ◽

Kidney Transplant ◽

Mixed Effects Models ◽

Karnofsky Performance Scale ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Adult Kidney ◽

The Mean ◽

Separate Cohort ◽

Performance Scale

Abstract Frailty and disabilities are highly prevalent among kidney transplant (KT) recipients, but are not routinely measured in KT recipients. The Karnofsky Performance Scale (KPS) is a clinically perceived measure used to evaluate patient’s ability to manage daily activities, but little is known about its post-KT trajectories and its relationship to frailty and disability in KT recipients. We leveraged a cohort of 159,992 adult KT recipients from SRTR (1/2005-6/2018) and a cohort of 1,106 adult KT recipients from a prospective cohort study on aging and KT with recorded KPS (range 10%-100% integers). In each separate cohort, we used mixed effects models to assess differences in trajectories of KPS post-KT. In 159,992 KT recipients in SRTR, the mean unadjusted KPS score was 88.34% (95%CI: 88.28%, 88.40%) and declined at a rate of -0.59%/year (95%CI: -0.61%, -0.57%) post-KT, such that by 2-years post-KT the average was 87.00% (95%CI: 86.94%, 87.05%). Age at KT was associated with steeper decline in KPS (p0.05). KPS is a measure of functional status distinct from frailty, ADL, IADL, and SPPB at KT admission that declines with older age post-KT. Older KT recipients should be monitored closely for declines in physical function, and potentially undergo prehabilitation to improve functional status post-KT.

Download Full-text

An Integrative Literature Review of Physical Activity Recommendations for Adult Renal Transplant Recipients

Progress in Transplantation ◽

10.1177/1526924816664079 ◽

2016 ◽

Vol 26 (4) ◽

pp. 381-385 ◽

Cited By ~ 3

Author(s):

Tara O’Brien ◽

Donna Hathaway

Keyword(s):

Physical Activity ◽

Kidney Transplant ◽

Data Extraction ◽

Cochrane Library ◽

Renal Transplant Recipients ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Physically Active ◽

Physical Activity Interventions ◽

Adult Kidney

Objective: To establish the current state of knowledge regarding physical activity interventions for adult kidney transplant recipients. Data Sources: A comprehensive literature search was conducted for the years 2009 to 2015 using 5 electronic databases: PubMed, CINAHL, Cochrane Library, Ovid, and ScienceDirect. Data Extraction: Of the 110 articles identified, only 6 met inclusion requirements. These studies were conducted between 2009 and 2015 and found that weight gain was reported most often within the first year of transplantation and that kidney transplant recipients desired early interventions to help them become more physically active. Conclusion: Further research is recommended to design age-appropriate physical activity interventions among this aging population living with a chronic condition known to have a high prevalence of obesity and cardiovascular disease.

Download Full-text

Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients

Transfusion and Apheresis Science ◽

10.1016/j.transci.2019.06.031 ◽

2019 ◽

Vol 58 (4) ◽

pp. 515-524

Author(s):

Mathilde Tamain ◽

Johnny Sayegh ◽

Arnaud Lionet ◽

Philippe Grimbert ◽

Carole Philipponnet ◽

...

Keyword(s):

Kidney Transplant ◽

Graft Rejection ◽

Extracorporeal Photopheresis ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Adult Kidney

Download Full-text

Standard induction with basiliximab versus no induction in low immunological risk kidney transplant recipients: study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-021-05253-1 ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Aziza Ajlan ◽

Hassan Aleid ◽

Tariq Zulfiquar Ali ◽

Hala Joharji ◽

Khalid Almeshari ◽

...

Keyword(s):

Kidney Transplant ◽

De Novo ◽

Controlled Trial ◽

Controlled Clinical Trial ◽

First Year ◽

Transplant Recipients ◽

Kidney Transplant Recipients ◽

Double Blind ◽

Donor Specific Antibodies

Abstract Background Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first-line agent in low immunological risk kidney transplant recipients. However, the role of IL2-RA in the setting of tacrolimus-based immunosuppression has not been fully investigated. Aims To compare different induction therapeutic strategies with 2 doses of basiliximab vs. no induction in low immunologic risk kidney transplant recipients as per KFSHRC protocol. Methods Prospective, randomized, double blind, non-inferiority, controlled clinical trial Expected outcomes 1. Primary outcomes: Biopsy-proven acute rejection within first year following transplant 2. Secondary outcomes: a. Patient and graft survival at 1 year b. eGFR at 6 months and at 12 months c. Emergence of de novo donor-specific antibodies (DSAs) Trial registration The study has been prospectively registered at clinicaltrials.gov (NTC: 04404127). Registered on 27 May 2020.

Download Full-text